Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Next Previous
X
Search
Trial Profile

A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATG 101 (Primary)
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms PROBE-CN
  • Sponsors Antengene Corporation

    • Most Recent Events

    • 02 Aug 2022 According to an Antengene Corporation media release, first patient has been dosed in this trial, Shanghai East Hospital of Tongji University is the lead site for the study,which will be conducted at four centers across China; Professor Ye Guo is principal investigator of the study.
    • 02 Aug 2022 Status changed from planning to recruiting as per Antengene Corporation media release
    • 10 Mar 2022 According to an Antengene Corporation media release, China National Medical Products Administration (NMPA) has approved IND for this phase I study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top